Assistant Professor
Dana-Farber Cancer Institute
Boston, Massachusetts
My focus in the advancement of clinical research and optimizing clinical care outcomes for Multiple Myeloma (MM) patients. Many marginalized populations are under represented in clinical trials and have minimal access to newer immunologic and cellular therapies. My goal is to improve treatment and clinical trial access, to allow for equitable access for all MM patients of diverse populations, including the marginalized populations, such as people of African descent who have an increased prevalance for precursor conditions leading to MM and increased prevalence of MM.